JP2015529655A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529655A5
JP2015529655A5 JP2015525554A JP2015525554A JP2015529655A5 JP 2015529655 A5 JP2015529655 A5 JP 2015529655A5 JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015529655 A5 JP2015529655 A5 JP 2015529655A5
Authority
JP
Japan
Prior art keywords
registered trademark
statin
simvastatin
subject
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015525554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053007 external-priority patent/WO2014022551A1/en
Publication of JP2015529655A publication Critical patent/JP2015529655A/ja
Publication of JP2015529655A5 publication Critical patent/JP2015529655A5/ja
Pending legal-status Critical Current

Links

JP2015525554A 2012-08-02 2013-07-31 アテローム性硬化症の処置方法 Pending JP2015529655A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261678992P 2012-08-02 2012-08-02
US61/678,992 2012-08-02
US201261695850P 2012-08-31 2012-08-31
US201261695807P 2012-08-31 2012-08-31
US61/695,807 2012-08-31
US61/695,850 2012-08-31
PCT/US2013/053007 WO2014022551A1 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017195835A Division JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法

Publications (2)

Publication Number Publication Date
JP2015529655A JP2015529655A (ja) 2015-10-08
JP2015529655A5 true JP2015529655A5 (enExample) 2016-09-15

Family

ID=50028503

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015525554A Pending JP2015529655A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2015525555A Pending JP2015524439A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2017194137A Pending JP2018016637A (ja) 2012-08-02 2017-10-04 アテローム性硬化症の処置方法
JP2017195835A Pending JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法
JP2019042213A Pending JP2019108389A (ja) 2012-08-02 2019-03-08 アテローム性硬化症の処置方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015525555A Pending JP2015524439A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2017194137A Pending JP2018016637A (ja) 2012-08-02 2017-10-04 アテローム性硬化症の処置方法
JP2017195835A Pending JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法
JP2019042213A Pending JP2019108389A (ja) 2012-08-02 2019-03-08 アテローム性硬化症の処置方法

Country Status (8)

Country Link
US (5) US10201585B2 (enExample)
EP (6) EP3300740A1 (enExample)
JP (5) JP2015529655A (enExample)
CN (3) CN104661670A (enExample)
AU (4) AU2013296494B2 (enExample)
CA (2) CA2880643A1 (enExample)
HK (2) HK1210962A1 (enExample)
WO (2) WO2014022551A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
MX2015005102A (es) * 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11355245B2 (en) * 2016-05-03 2022-06-07 International Business Machines Corporation Identifying and ranking risk factors using trained predictive models
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202005439D0 (en) 2020-04-14 2020-05-27 Aurigen Medical Ltd A device for occlusion of a left a trial appendage of a heart

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2003014145A2 (en) * 2001-08-10 2003-02-20 Novartis Ag Peptides that bind to atherosclerotic lesions
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
EP3260127B1 (en) * 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
AU2007209859A1 (en) 2006-01-30 2007-08-09 Israel Ben David Bryson Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients
ES2532595T3 (es) * 2006-08-30 2015-03-30 Kyushu University, National University Corporation Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
US20090192095A1 (en) 2008-01-18 2009-07-30 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
PL2252312T3 (pl) * 2008-02-07 2014-10-31 Univ Cornell Sposoby zapobiegania lub leczenia insulinooporności
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法

Similar Documents

Publication Publication Date Title
JP2015529655A5 (enExample)
JP2015524439A5 (enExample)
Ito Dyslipidemia: management using optimal lipid-lowering therapy
AU2013296493B2 (en) Methods for treatment of atherosclerosis
Jones et al. Role of colesevelam in combination lipid-lowering therapy
Marcus et al. Alternate-day dosing with statins
JP2018508551A5 (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
Trentman et al. Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
Backes et al. Optimal lipid modification: the rationale for combination therapy
Markel Statins and peripheral arterial disease
Stein Management of dyslipidemia in the high-risk patient
Pflieger et al. Medical management of stable coronary artery disease
JP2010505866A5 (enExample)
EP1945205A2 (en) Methods and compositions for treating disorders associated with hyperlipidemia in a mammal
Woo et al. Comparison of the efficacy and safety of atorvastatin 40 mg/ω-3 fatty acids 4 g fixed-dose combination and atorvastatin 40 mg monotherapy in hypertriglyceridemic patients who poorly respond to atorvastatin 40 mg monotherapy: an 8-week, multicenter, randomized, double-blind Phase III Study
Lin et al. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients
Ho et al. Statins and their interactions with other lipid-modifying medications: safety issues in the elderly
Michos et al. Lipid-lowering for the prevention of cardiovascular disease in the new era: a practical approach to combination therapy: lipid-lowering and combination therapy
Katsiki et al. Exploring the management of statin intolerant patients: 2016 and beyond
McGovern Niaspan®: creating a new concept for raising HDL-cholesterol
Davidson Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
Moro et al. Non-antiarrhythmic drugs to prevent atrial fibrillation
Castaldo A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients
Korth et al. Hepatotoxic Effects of Lipid-altering Agents
CA2822921A1 (en) Gemcabene and derivatives thereof for treating or preventing pancreatitis